Evidence map›Paper›PMID 41206843›Full record

ArticleBiological trace element research2026

Inhibitory Effect of TrxR Inhibitor Ag (Ⅰ) Schiff Base Complex Against Cervical Cancer Via ROS-mediated ASK1/MAPK Signaling and Autophagy.

Jian-Jun Liu, Jia-Hua Zou, Bin Dong, Xue-Ping Lu, Li-Feng Chen, San-Mei Ma, Zhong Liu

Abstract read
PubMed Publisher
In one paragraph

Article in Biological trace element research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jian-Jun LiuGuangdong Provincial Key Laboratory of Bioengineering Medicine, National Engineering Research Center of Genetic Medicine, Institute of Biomedicine, College of Life Science and Technology, Jinan University, Guangzhou, 510632, China.
Jia-Hua ZouGuangdong Provincial Key Laboratory of Bioengineering Medicine, National Engineering Research Center of Genetic Medicine, Institute of Biomedicine, College of Life Science and Technology, Jinan University, Guangzhou, 510632, China.
Bin DongCollege of Bee Science and Biomedicine, Fujian Agriculture and Forestry University, Fujian, 350002, China.
Xue-Ping LuGuangdong Provincial Key Laboratory of Bioengineering Medicine, National Engineering Research Center of Genetic Medicine, Institute of Biomedicine, College of Life Science and Technology, Jinan University, Guangzhou, 510632, China.
Li-Feng ChenDepartment of Biochemistry, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China. 1530728227@qq.com.
San-Mei MaDepartment of Bioengineering, Jinan University, Guangzhou, 510632, Guangdong, China. msmwdw@163.com.
Zhong LiuGuangdong Provincial Key Laboratory of Bioengineering Medicine, National Engineering Research Center of Genetic Medicine, Institute of Biomedicine, College of Life Science and Technology, Jinan University, Guangzhou, 510632, China. tliuzh@jnu.edu.cn.

Funding

Basic and Applied Basic Research Foundation of Guangdong No. 2021A1515220126National Natural Science Foundation of China No.82073864; 82273979; 82204464
6 · The paper itself

Abstract

Schiff base complexes possess many biological activities, including antibacterial and antitumor activities. However, the anti-cervical cancer activity of Ag (Ⅰ) Schiff base complex or its corresponding molecular mechanism remains limited. Here, we showed that Ag (Ⅰ) Schiff base complex Ag34 significantly inhibited the proliferation of cervical cancer cells. Subsequent studies on the anti-cervical cancer mechanism of Ag34 revealed that Ag34 inactivated TrxR, which led to ROS accumulation. Ag34-induced ROS accumulation promoted ASK1/MAPK signaling activation and autophagy, thereby triggering apoptosis of cervical cancer cells. Taken together, Ag34 has the potential to be used in the treatment of cervical cancer.

Indexed as

Antineoplastic AgentsAutophagyMAP Kinase Kinase Kinase 5MAP Kinase Signaling SystemReactive Oxygen SpeciesUterine Cervical NeoplasmsApoptosisCell ProliferationFemaleHeLa CellsHumansSchiff BasesAntineoplastic AgentsMAP3K5 protein, humanMAP Kinase Kinase Kinase 5Reactive Oxygen SpeciesSchiff BasesAg (Ⅰ) schiff base complexesApoptosisCervical cancerROSTrxR

Identifiers

PMID41206843

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.